Seasonale

See also: Generic Seasonique

Seasonale is a brand name of ethinyl estradiol/levonorgestrel, approved by the FDA in the following formulation(s):

SEASONALE (ethinyl estradiol; levonorgestrel - tablet; oral)

• 
  Manufacturer: DURAMED RES
  
  Approval date: September 5, 2003
  
  Strength(s): 0.03MG;0.15MG ^[RLD][AB]

Has a generic version of Seasonale been approved?

A generic version of Seasonale has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Seasonale and have been approved by the FDA:

INTROVALE (ethinyl estradiol; levonorgestrel tablet; oral)

• 
  Manufacturer: SANDOZ
  
  Approval date: September 27, 2010
  
  Strength(s): 0.03MG;0.15MG ^[AB]

QUASENSE (ethinyl estradiol; levonorgestrel tablet; oral)

• 
  Manufacturer: WATSON LABS
  
  Approval date: September 6, 2006
  
  Strength(s): 0.03MG;0.15MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Seasonale. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
  Patent 5,898,032
  Issued: April 27, 1999
  Inventor(s): Hodgen; Gary D.
  Assignee(s): Medical College of Hampton Roads
  A method of female contraception involves administering a combination of estrogen and progestin for 60-110 consecutive days in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively. The advantages include less menstrual bleeding, less patient anemia, less total exposure to medication, higher compliance rates and more lifestyle convenience for patients.
  
  Patent expiration dates:
  
  
  • June 23, 2017
    
    ✓ 
    Patent use: PREVENTION OF PREGNANCY
  
  



• 
  Methods of extended use oral contraception
  Patent RE39861
  Issued: September 25, 2007
  Inventor(s): Hodgen; Gary D.
  Assignee(s): Duramed Pharmaceuticals, Inc.
  A method of female contraception involves administering a combination of estrogen and progestin for 60-110 consecutive days in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively. The advantages include less menstrual bleeding, less patient anemia, less total exposure to medication, higher compliance rates and more lifestyle convenience for patients.
  
  Patent expiration dates:
  
  
  • June 23, 2017
    
    ✓ 
    Patent use: PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
  
  

See also...

• Seasonale Consumer Information (Drugs.com)
• Seasonale Consumer Information (Wolters Kluwer)
• Seasonale extended-cycle Consumer Information (Cerner Multum)
• Levonorgestrel/Ethinyl Estradiol Consumer Information (Wolters Kluwer)
• Ethinyl estradiol and levonorgestrel Consumer Information (Cerner Multum)
• Ethinyl estradiol and levonorgestrel extended-cycle Consumer Information (Cerner Multum)